Jittima Weerachayaphorn1, Maria Jimena Amaya2, Carlo Spirli2, Piyachat Chansela3, Kisha A Mitchell-Richards4, Meenakshisundaram Ananthanarayanan2, Michael H Nathanson5. 1. Liver Center, Yale University School of Medicine, New Haven, Connecticut; Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand. 2. Liver Center, Yale University School of Medicine, New Haven, Connecticut. 3. Department of Anatomy, Phramongkutklao College of Medicine, Bangkok, Thailand. 4. Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. 5. Liver Center, Yale University School of Medicine, New Haven, Connecticut. Electronic address: michael.nathanson@yale.edu.
Abstract
BACKGROUND & AIMS: Most cholestatic disorders are caused by defects in cholangiocytes. The type 3 isoform of the inositol 1,4,5-trisphosphate receptor (ITPR3) is the most abundant intracellular calcium release channel in cholangiocytes. ITPR3 is required for bicarbonate secretion by bile ducts, and its expression is reduced in intrahepatic bile ducts of patients with cholestatic disorders. We investigated whether the nuclear factor, erythroid 2-like 2 (NFE2L2 or NRF2), which is sensitive to oxidative stress, regulates expression of ITPR3. METHODS: The activity of the ITPR3 promoter was measured in normal human cholangiocyte (NHC) cells and primary mouse cholangiocytes. Levels of ITPR3 protein and messenger RNA were examined by immunoblot and polymerase chain reaction analyses, respectively. ITPR3 activity was determined by measuring calcium signaling in normal human cholangiocyte cells and secretion in isolated bile duct units. Levels of NRF2 were measured in liver tissues from rats with cholestasis (induced by administration of α-napthylisothiocyanate) and from patients with biliary diseases. RESULTS: We identified a musculo-aponeurotic fibrosarcoma recognition element in the promoter of ITPR3 that bound NRF2 directly in NHC cells and mouse cholangiocytes. Increasing binding of NRF2 at this site resulted in chromatin remodeling that reduced promoter activity. Mutant forms of the musculo-aponeurotic fibrosarcoma recognition element did not bind NRF2. Activation of NRF2 with quercetin or by oxidative stress reduced expression of ITPR3 and calcium signaling in NHC cells; quercetin also reduced secretion by bile duct units isolated from rats. Knockdown of NRF2 with small interfering RNAs restored expression and function of ITPR3 in NHC cells incubated with quercetin. Bile ducts from rats with cholestasis and patients with cholangiopathic disorders expressed higher levels of NRF2 and lower levels of ITPR3 than ducts from control rats or patients with other liver disorders. CONCLUSIONS: The transcription factor NRF2 binds to the promoter of ITPR3 to inhibit its expression in cholangiocytes, leading to reduced calcium signaling and bile duct secretion. This could be a mechanism by which oxidative stress inhibits these processes and contributes to cholangiopathies.
BACKGROUND & AIMS: Most cholestatic disorders are caused by defects in cholangiocytes. The type 3 isoform of the inositol 1,4,5-trisphosphate receptor (ITPR3) is the most abundant intracellular calcium release channel in cholangiocytes. ITPR3 is required for bicarbonate secretion by bile ducts, and its expression is reduced in intrahepatic bile ducts of patients with cholestatic disorders. We investigated whether the nuclear factor, erythroid 2-like 2 (NFE2L2 or NRF2), which is sensitive to oxidative stress, regulates expression of ITPR3. METHODS: The activity of the ITPR3 promoter was measured in normal human cholangiocyte (NHC) cells and primary mouse cholangiocytes. Levels of ITPR3 protein and messenger RNA were examined by immunoblot and polymerase chain reaction analyses, respectively. ITPR3 activity was determined by measuring calcium signaling in normal human cholangiocyte cells and secretion in isolated bile duct units. Levels of NRF2 were measured in liver tissues from rats with cholestasis (induced by administration of α-napthylisothiocyanate) and from patients with biliary diseases. RESULTS: We identified a musculo-aponeurotic fibrosarcoma recognition element in the promoter of ITPR3 that bound NRF2 directly in NHC cells and mouse cholangiocytes. Increasing binding of NRF2 at this site resulted in chromatin remodeling that reduced promoter activity. Mutant forms of the musculo-aponeurotic fibrosarcoma recognition element did not bind NRF2. Activation of NRF2 with quercetin or by oxidative stress reduced expression of ITPR3 and calcium signaling in NHC cells; quercetin also reduced secretion by bile duct units isolated from rats. Knockdown of NRF2 with small interfering RNAs restored expression and function of ITPR3 in NHC cells incubated with quercetin. Bile ducts from rats with cholestasis and patients with cholangiopathic disorders expressed higher levels of NRF2 and lower levels of ITPR3 than ducts from control rats or patients with other liver disorders. CONCLUSIONS: The transcription factor NRF2 binds to the promoter of ITPR3 to inhibit its expression in cholangiocytes, leading to reduced calcium signaling and bile duct secretion. This could be a mechanism by which oxidative stress inhibits these processes and contributes to cholangiopathies.
Authors: R Brian Doctor; Thomas Matzakos; Ryan McWilliams; Sylene Johnson; Andrew P Feranchak; J Gregory Fitz Journal: Am J Physiol Gastrointest Liver Physiol Date: 2004-11-04 Impact factor: 4.052
Authors: Erick Hernandez; M Fatima Leite; Mateus T Guerra; Emma A Kruglov; Oscar Bruna-Romero; Michele A Rodrigues; Dawidson A Gomes; Frank J Giordano; Jonathan A Dranoff; Michael H Nathanson Journal: J Biol Chem Date: 2007-02-06 Impact factor: 5.157
Authors: Xiao Zhao; Kristin Lorent; Benjamin J Wilkins; Dylan M Marchione; Kevin Gillespie; Orith Waisbourd-Zinman; Juhoon So; Kyung Ah Koo; Donghun Shin; John R Porter; Rebecca G Wells; Ian Blair; Michael Pack Journal: Hepatology Date: 2016-06-11 Impact factor: 17.425
Authors: Pimwipa Ueasilamongkol; Tanaporn Khamphaya; Mateus T Guerra; Michele A Rodrigues; Dawidson A Gomes; Yong Kong; Wei Wei; Dhanpat Jain; David C Trampert; Meenakshisundaram Ananthanarayanan; Jesus M Banales; Lewis R Roberts; Farshad Farshidfar; Michael H Nathanson; Jittima Weerachayaphorn Journal: Hepatology Date: 2019-08-19 Impact factor: 17.425
Authors: Andressa Franca; Antonio Carlos Melo Lima Filho; Mateus T Guerra; Jittima Weerachayaphorn; Marcone Loiola Dos Santos; Basile Njei; Marie Robert; Cristiano Xavier Lima; Paula Vieira Teixeira Vidigal; Jesus M Banales; Meenakshisundaram Ananthanarayanam; M Fatima Leite; Michael H Nathanson Journal: Hepatology Date: 2018-12-31 Impact factor: 17.425
Authors: Antônio Carlos Melo Lima Filho; Andressa França; Rodrigo M Florentino; Marcone Loiola Dos Santos; Fernanda de Oliveira Lemos; Dabny Goulart Missiaggia; Roberta Cristelli Fonseca; André Gustavo Oliveira; Meenakshisundaram Ananthanarayanan; Mateus T Guerra; Matheus de Castro Fonseca; Paula Vieira Teixeira Vidigal; Cristiano Xavier Lima; Michael H Nathanson; M Fatima Leite Journal: Cell Calcium Date: 2020-08-11 Impact factor: 6.817
Authors: Kemper Nunes Dos Santos; Rodrigo M Florentino; Andressa França; Antônio Carlos Melo Lima Filho; Marcone Loiola Dos Santos; Dabny Missiaggia; Matheus de Castro Fonseca; Igor Brasil Costa; Paula Vieira Teixeira Vidigal; Michael H Nathanson; Fernanda de Oliveira Lemos; M Fatima Leite Journal: Int J Mol Sci Date: 2019-07-23 Impact factor: 5.923
Authors: Fernanda de Oliveira Lemos; Rodrigo M Florentino; Antônio Carlos Melo Lima Filho; Marcone Loiola Dos Santos; M Fatima Leite Journal: World J Gastroenterol Date: 2019-11-28 Impact factor: 5.742
Authors: Sona Hudecova; Jana Markova; Veronika Simko; Lucia Csaderova; Tibor Stracina; Marta Sirova; Michaela Fojtu; Eliska Svastova; Paulina Gronesova; Michal Pastorek; Marie Novakova; Dana Cholujova; Juraj Kopacek; Silvia Pastorekova; Jan Sedlak; Olga Krizanova Journal: Oncotarget Date: 2016-09-20